GSK presents positive data for AREXVY, its respiratory syncytial virus ...
WEB2 days ago · GSK plc (LSE/NYSE: GSK) today announced new data from the AReSVi-006 (Adult Respiratory Syncytial Virus) phase III trial evaluating the efficacy and safety of a single dose of AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) against lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in …
GSK reports positive findings from Phase III RSV vaccine trial
WEB1 day ago · GSK has unveiled positive data from its Phase III AReSVi-006 clinical trial of Arexvy, its RSV vaccine, which aims to prevent lower respiratory tract disease (LRTD) over three RSV seasons.
GSK RSV shot 43% effective against severe disease in third year
WEB1 day ago · GSK said on Tuesday that its Arexvy respiratory syncytial virus vaccine was 43.3% effective in preventing severe illness in its third season after patients received the shot.
GSK Says RSV Vaccine Offers Protection Over Three Seasons
WEB1 day ago · GSK Plc’s shot for respiratory syncytial virus provided protection across three seasons after vaccination, the company said Tuesday.
GSK Presents Positive Data for AREXVY, Its Respiratory Syncytial Virus ...
WEB2 days ago · GSK Presents Positive Data for AREXVY, Its Respiratory Syncytial Virus (RSV) Vaccine, Indicating Protection Over Three RSV Seasons. GSK’s RSV vaccine is the only RSV vaccine with...
GSK Presents Positive Data for AREXVY, Its Respiratory Syncytial Virus ...
WEB1 day ago · GSK’s RSV vaccine is the only RSV vaccine with efficacy and safety data available through three full seasons, including in people at increased risk. Safety and reactogenicity data are...
US FDA approves GSK’s AREXVY, the world’s first respiratory …
WEBMay 3, 2023 · US FDA approves GSK’s AREXVY, the world’s first respiratory syncytial virus (RSV) vaccine for older adults. Ground-breaking approval enables adults aged 60 years and older to be protected from RSV disease for the first time.
New data for AREXVY, GSK’s RSV vaccine, show potential to help …
WEBOct 25, 2023 · New data for AREXVY, GSK’s RSV vaccine, show potential to help protect adults aged 50 to 59 at increased risk for RSV disease. Preliminary results from phase III trial show primary endpoints met, with non-inferior immune responses observed in adults aged 50-59 compared to adults aged 60 and older.
About Arexvy (respiratory syncytial virus vaccine, adjuvanted) - GSK
WEBJun 21, 2023 · New results from the ongoing AReSVi-006 phase III trial show vaccine efficacy against RSV-lower respiratory tract disease and severe disease over two full RSV seasons, including in participants with underlying medical conditions
GSK’s Widely Used RSV Shot Retains 43% Potency In Third Year, …
WEB14 hours ago · U.S. sales of RSV vaccines from GSK (GSK.L) and Pfizer (PFE.N) are down significantly after regulators narrowed the targeted age group and said it was a once-in-a-lifetime shot for now, excluding millions of people who got one last year.